Advancing Myeloma Care: Immunotherapy Trials Now Underway at Sylvester Center image

Advancing Myeloma Care: Immunotherapy Trials Now Underway at Sylvester Center

Jun 26, 2025
04:00PM - 05:00PM EDT
Online Event
Overview

Join us for an informative webinar with Dickran Kazandjian, MD from the University of Miami Sylvester Comprehensive Cancer Center as he shares details about two promising clinical trials for newly diagnosed multiple myeloma patients. The Immunoplant trial explores immunotherapy as a potential alternative to stem cell transplant, using linvoseltamab (a BCMA and CD3-targeting therapy) to deepen the response of patients who are in VGPR but MRD+ after induction and the Alp d’Huez trial focused on patients in early maintenance. Learn who may qualify, how these approaches work, and what they could mean for the future of myeloma care. A Q&A session will follow the presentation.

Agenda
4:00 PM
Introductions
Cynthia Cahoon, RN

Cynthia introduces the agenda of the event and featured speaker Dr. Dickran Kazandjian

4:05 PM
Presentation
Dickran Kazandjian, MD

Dr. Kazandjian shares details about two promising clinical trials for newly diagnosed multiple myeloma patients

4:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Cynthia Cahoon, RN

Cynthia Cahoon, RN

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Healthtree contact Dickran Kazandjian, MD

Dickran Kazandjian, MD

Dr. Kazandjian’s clinical and translational research interests lie in the treatment of precursor plasma cell disorders including high risk smoldering multiple myeloma and the role of immunotherapy in plasma cell dyscrasias. In addition, he is re-evaluating the role of autologous stem cell transplant (ASCT) in the era of highly efficacious novel-novel drugs, immunotherapy biologics, and cell-based therapies with the hypothesis that certain subsets of patients with myeloma may not benefit by default upfront ASCT.